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Introduction
Interstitial lung disease (ILD), including idiopathic interstitial pneumonias, is a heterogeneous group of diffuse parenchymal lung diseases [1, 2 ] . The clinical outcome of ILD can be favorable, however in a substantial percentage of patients the course is progressive. Examples are patients suffering from idiopathic pulmonary fibrosis and severe sarcoidosis. In a substantial number of those cases immunosuppressive drugs, like mercaptopurines, are potential candidates in the treatment regimens [3] [4] [5] [6] [7] [8] . In 3-5% of the patients these drugs give rise to serious adverse drug reactions (ADRs) like myelosuppression, elevated liver functions, pancreatitis and flu-like symptoms [9] . In immune-compromised patients this will lead to hospitalization or at least intensified medical surveillance.
Most of these ADRs are due to a reduced or absent activity of drug metabolizing enzyme systems. These defects may be either genetically determined or acquired [10] . The study of the interaction between genetic make up and therapeutic compounds is termed pharmacogenetics.
Drug metabolism is divided in two phases -phase I and phase II. Phase I reactions include oxidation, reduction and hydrolysis of the drug. The cytochrome P-450 group of enzymes mediates the majority of these reactions. Phase II drug metabolism includes reactions in which the drug is conjugated, that is acetylated, glucuronidated or methylated [11] [12] [13] .
Mercaptopurines are a class of immunosuppressive antimetabolites used for the treatment of a wide array of diseases, including ILD. Due to their extensive use, ADRs in mercaptopurine-based therapeutic regimens occur frequently, potentially having fatal consequences. In this paper we will address ADRs caused by mercaptopurine therapy in relation to defects in purine metabolism.
Mercaptopurine metabolism
The mercaptopurine-based drugs, azathioprine, 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are used as immunosuppressants in the treatment of autoimmune disorders, inflammatory bowel disease, debilitating skin diseases and various inflammatory eye conditions and as antiproliferative drugs in childhood acute lymphoblastic leukemia [14 ,15 ,16,17 ,18 ] .
Azathioprine is a pro-drug of 6-MP, which is activated by glutathione-S-transferase-dependent enzymatic cleavage, releasing the methyl-nitro-thioimidazole moiety from the azathioprine molecule, generating 6-MP (see Fig. 1 ).
Approximately 1% of the 6-MP thus generated is activated by hypoxanthine-guanine phosphoribosyl transferase (HGPRT), a salvage enzyme in purine metabolism, producing 6-thioinosine monophosphate (6-TIMP). Eighty-four per cent of the activated 6-MP is subjected to oxidation by xanthine oxidase to 6-thiouric acid. Aldehyde oxidase is also capable of oxidizing 6-MP: it catalyzes the conversion of 6-MP and 6-TG to their 8-hydroxy analogues. The importance of this deactivation pathway is less clear [19, 20] .
Another important deactivation route, handling 15% of the generated 6-MP, is methylation catalyzed by mercaptopurine methyltransferase (TPMT). Deactivation of 6-MP by TPMT yields 6-methylmercaptopurine (6-MMP) [21, 22] .
After activation of mercaptopurine to 6-TIMP, this metabolite is further metabolized to 6-thioguanine monophosphate (6-TGMP) by successively inosinemonophosphate dehydrogenase (IMPDH) and guanosine-monophosphate synthetase (GMPS). 6-TGMP is the precursor of the cytotoxic 6-thioguanine (deoxy) ribonucleotide 5 0 -triphosphates, which are incorporated into DNA and RNA, respectively.
As shown in Fig. 1, 6 -TIMP is also deactivated by TPMT, resulting in the formation of 6-Me-TIMP.
6-TG is activated in a similar fashion as 6-MP. The first activation step is catalyzed by HGPRT, yielding 6-TGMP. Further metabolization is catalyzed by nucleotide kinases, resulting in the formation of the above-mentioned cytotoxic (deoxy)ribonucleotide 5 0 -triphosphates of 6-thioguanine. 6-TG is deactivated either by methylation by TPMT or by degradation through guanine deaminase and xanthine oxidase to thiouric acid.
Another key enzyme in mercaptopurine metabolism is inosine triphosphate pyrophosphohydrolase (ITPase). This enzyme is responsible for the pyrophosphohydrolysis of 6-thioinosine triphosphate (6-TITP), one of the metabolites of 6-TIMP. Deficiency or a decreased activity of this enzyme results in a surplus of (thio)ionosine triphosphates, which disturbs the equilibrium in the cellular (deoxy) nucleotide triphosphate pool: for example, ITP can compete with GTP in GTP-driven reactions [23] .
Another pathway for detoxification of mercaptopurine is degradation of nucleotides to nucleosides catalyzed by purine-5 0 -nucleotidase (5 0 -NT). Both 6-TIMP and 6-TGMP are substrates for 5 0 -NT, although at higher concentrations of these thionucleotides substrate inhibition has been observed [24] .
Pharmacogenetic defects responsible for mercaptopurine toxicity
As can be seen in Fig. 1 , mercaptopurine metabolism is an intricate process involving a large number of enzymes. It is not hard to imagine that a decreased activity of one of the enzymes involved in this process gives rise to an accumulation of metabolites. Depending on which enzyme is deficient, metabolites can accumulate in specific tissues and reach concentration levels at which they become cytotoxic, thus giving rise to ADR. The characteristics are summarized in Table 1 . GDA, guanine deaminase; GMPS, guanosine monophosphate synthase; HGPRT, hypoxanthine-guanine phosphoribosyl transferase; IMPDH, inosine monophosphate dehydrogenase; ITPA, inosine triphosphate pyrophosphohydrolase; 6-MP, 6-mercaptopurine; 6-MMP, 6-methylmercaptopurine; 6-MTIM(D/T)P, 6-methylthioinosine mono(di/tri)phosphate; 6-MTG, 6-methylthioguanine; NM(D)PK, nucleotide mono(di)phosphate kinase; 5 0 -NT, 5 0 -nucleotidase; 6-TG, 6-thioguanine; 6-TGM(D/T)P, 6-thioguanine mono(di/tri)phosphate; TPMT, thiopurine-S-methyltransferase; TU, thiouric acid; TX, thioxanthine; 6-TXMP, 6-thioxanthosine monophosphate; XO, xanthine oxidase.
Although nonresponsiveness to mercaptopurine therapy is not per definition an ADR, it is worthwhile mentioning this phenomenon in the current context. Nonresponsiveness in mercaptopurine therapy in the case of azathioprine can be due to a diminished activity of glutathione-S-transferase or a lack of available glutathione. Prolonged treatment with azathioprine/6-MP can give rise to a depletion of available glutathione [5, 25 ].
Another frequently noted reaction to azathioprine therapy is the occurrence of a rash. This is assigned to an allergic reaction to the release of the imidazole moiety of azathioprine [26] .
Recently, nonresponsiveness to mercaptopurine therapy in human leukemia cell lines was associated with impaired transport of mercaptopurines into the cell [27 ] .
As was pointed out before, activation of 6-MP to 6-TIMP is mediated by HGPRT. A complete deficiency of this enzyme leads to the clinically distinct phenotype of Lesch Nyhan syndrome; the partial deficiency mainly occurs in females and presents with a much milder phenotype. When 6-MP is given to patients with partial hypoxanthine phosphoribosyltransferase (HPRT) deficiency a diminished response on 6-MP therapy, as measured by 6-thioguanine nucleotide (6-TGN) formation, is noted. There are high concentrations of 6-MMP metabolites relative to the concentration of 6-TGN in peripheral red blood cells. Substituting 6-TG for 6-MP is of no use, because 6-TG activation also depends on HPRT [28] .
A diminished in-vivo activity of xanthine oxidase may have serious consequences in mercaptopurine therapy. About 85% of the bio-available 6-MP is deactivated by xanthine oxidase to thiouric acid in the liver and the intestine [29] . After deamination by guanidine deaminase, 6-TG is deactivated by the same pathway. Theoretically a lowered xanthine oxidase activity will result in an increased availability of 6-MP for either methylation by TPMT or further activation to 6-TIMP by HPRT. The result is an increased concentration of 6-MMP relative to 6-TGN concentrations. As far as we know, patients with an increased 6-MMP and relatively normal amount of 6-TG are not routinely checked for xanthine oxidase activity [21] . Studies using a combination therapy of 6-MP and allopurinol, a xanthine oxidase inhibitor, in patients not responding to 6-MP/azathioprine therapy showed an increase in 6-TGN availability when compared with azathioprine therapy only. The doses of azathioprine in the combined therapy were lowered in order to avoid toxic effects on the bone marrow of an increased supply of 6-MP. This finding suggests a key role for xanthine oxidase in mercaptopurine therapy, in which tissue distribution of xanthine oxidase may be of importance in understanding this role [21, 30] . The antifolate drug methotrexate also has an inhibitory effect on xanthine oxidase and care has to be taken when methotrexate is combined with 6-MP/ azathioprine therapy [29] .
The most extensively studied enzyme in the mercaptopurine utilization pathway is TPMT [31 ] . As is described by Gunnarsdottir et al. [32] , TPMT is active at nearly all steps of the mercaptopurine pathway. The importance of TPMT is underlined in the effects that appear when the activity of the enzyme is altered, both decreased or increased [33 ] .
TPMT activity in the normal population has a trimodal distribution: 0.3% low activity, 11% intermediate activity and 89% normal to high activity [34] . A high activity of TPMT results in the formation of relatively high intracellular concentrations of 6-MMP and subsequently a decreased concentration of 6-TGN. In these patients the efficacy of azathioprine or 6-MP is less than in patients with a normal or low TPMT activity as the 6-TGNs are the therapeutically active metabolites [35] . High levels of 6-MMP are associated with hepatotoxicity (elevated transaminases) [36, 37 ] . The methylation product of TIMP, 6-MTIMP, inhibits the purine de-novo synthesis. The consequence of this inhibition is a depletion of the available (deoxy)nucleotides necessary for DNA and RNA synthesis [38] .
The methyl group necessary for the methylation of 6-MP and its nucleotides is donated by S-adenosyl methionine (SAM). An enhanced methylation rate may deplete SAM, possibly interfering with other metabolic processes requiring SAM. A decreased or absent TPMT activity results in increased synthesis of 6-TG metabolites from 6-MP. Especially in tissues without xanthine oxidase activity, like the bone marrow, 6-TGN will accumulate in high levels causing serious life-threatening myelosuppression [39 ,40 ] . For obvious reasons the dosage of 6-MP has to be reduced in order to avoid the ADR.
Recently the role of folic acid and the enzyme methylenetetrahydrofolate reductase (MTHFR), which catalyses the (re)methylation of homocysteine to methionine in mercaptopurine metabolism, has been studied. Breen et al. [22] studied the possible role of mutations in the MTHFR gene. There appeared, however, to be no correlation between polymorphisms in the gene encoding MTHR and azathioprine toxicity.
Due to the crucial role that TPMT has in mercaptopurine metabolism, measurement of erythrocyte TPMT activity is recommended before starting mercaptopurine-based treatment. In case a decreased TPMT activity is found, the therapeutic regimen can be adjusted. In daily clinical practice, TPMT phenotyping, that is measurement of TPMT activity, is preferred to genotyping. The results of TPMT phenotyping are usually available within 5 working days and exclude the risk of overlooking/missing novel mutations. Genotyping is used to establish the genetic base of a decreased activity of the enzyme. Ninety-five per cent of the reduced TPMT activities is accounted for by three common polymorphisms, that is TMPTÃ2, Ã3A and Ã3C [41] .
Another enzyme involved in mercaptopurine metabolism having pharmacogenetic consequences is ITPase [23, 42] . As shown in Fig. 1 , ITPase catalyses the pyrophosphohydrolysis of ITP to IMP. In mercaptopurine metabolism TITP is generated from TIMP, which is cycled back to TIMP by ITPase. TITP is also methylated by TPMT to 6-MTITP. The accumulating metabolites, TITP and 6-MTITP, are so-called 'rogue' nucleotides and may interfere with other nucleotides in RNA incorporation.
As with TPMT, the activity of ITPase is trimodally distributed. Lower activities are due to homozygosity or compound heterozygosity for one of the inactivating mutations in the ITPA gene. Heterozygous individuals for the 94C ! A polymorphism have low intermediate activities; patients with one IVS2 þ 21A ! C polymorphism have high intermediate or low normal activities of ITPase in peripheral red blood cells [43,44 ,45 ] . There are conflicting reports in the literature on the toxicity of mercaptopurines in heterozygotes and homozygous individuals [46] [47] [48] . It is recommended to adapt the therapeutic regimen by changing from 6-MP to 6-TG (Lanvis) in the case of decreased ITPase activity to avoid ADRs [39 ,49] .
Deficiency of 5 0 -NT leads to increased concentrations of 6-TGMP and 6-TIMP, the latter being methylated by TPMT to 6-MTIMP. In terms of ADRs, the consequences are inhibition of the purine de-novo synthesis by 6-MTIMP and higher cytotoxicity through accumulation of 6-TGMP [50, 51] . Although nowadays the focus is on TMPT and ITPase we consider this enzyme may be of equal importance in research on ADRs in mercaptopurine treatment.
Further activation of the mercaptopurines is catalyzed by IMPDH and GMPS. The role of IMPDH in mercaptopurine activation is still unclear. Theoretically one can presume ADRs in case of a reduced activity of IMPDH, which is the rate-limiting step in guanine nucleotide biosynthesis [52] . Investigations of IMPDH are mostly linked to the use of mycophenolic acid (MPA). MPA is an inhibitor of mammalian IMPDH and therefore can suppress de-novo GTP synthesis [53] . Azathioprine resistance in one patient was associated with a mutation in the P3 promotor region of IMPDH1 [54 ] .
Another enzyme involved in the GMP biosynthesis is GMPS. There is a suggestion in the literature about the possibility of using this enzyme in immunomodulating processes [55] .
Conclusion
The metabolism of mercaptopurines is an intricate network, requiring many enzymes. Defects in any of these enzymes will cause an alteration in mercaptopurine metabolism, some giving rise to the accumulation of highly toxic metabolites causing ADRs. In order to avoid ADRs it is strongly recommended that all patients, including patients suffering from ILD who are due to be treated with mercaptopurine (analogs) for disturbances in the activation/deactivation pathway of mercaptopurines, are tested for TPMT and ITPase activity before initiating therapy [44 ,56] .
With respect to the other enzymes involved in mercaptopurine metabolism, 5-NT, HGPRT and IMPDH are candidate enzymes for further investigation. Measurement of the enzyme activity is the first step in the process; mutation analysis of the gene is the second. The additional costs will be limited by this multi-step approach. During mercaptopurine therapy the patient must be monitored on a regular basis, both by measuring erythrocyte thionucleotide concentrations and by blood counts.
This approach is of high clinical relevance as it aims to reduce healthcare costs and to improve patients' quality of life [57 ,58 ,59] .
Including pharmacogenetics in therapeutic drug monitoring will lead to a more individualized pharmacotherapy [60] . Therefore, there is a need for implementation of this knowledge in daily clinical practice to ensure the benefits will be achieved [61] . 
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